Description

Cagrilintide – Amylin Analogue for Appetite & Metabolic Research

Cagrilintide 5 mg is a long-acting amylin analogue peptide engineered for enhanced stability, potency, and duration compared to natural amylin. It is designed to act on amylin and calcitonin receptors (AMY₁R) in the brain, where it regulates satiety, food intake, and energy balance.

Cagrilintide is being researched as a next-generation anti-obesity and metabolic peptide, both as a standalone compound and in combination with GLP-1 receptor agonists such as semaglutide (as in the investigational dual-therapy “CagriSema”).

Key Features & Research Applications

🍽 Appetite Regulation:
Reduces food intake and enhances post-meal satiety by mimicking natural amylin signaling in the hypothalamus.

📉 Weight Management Studies:
Demonstrated sustained weight reduction and improved fat metabolism in preclinical and clinical models.

🧬 Metabolic Regulation:
Improves insulin sensitivity and supports healthy glucose and lipid metabolism.

❤️ Combination Therapy Potential:
Used synergistically with GLP-1 analogs to achieve enhanced effects on weight loss and glycemic control.

🧠 Central Nervous System Research:
Investigated for its role in neuroendocrine signaling, appetite suppression, and energy homeostasis.

Product Details

• Name: Cagrilintide (AM833)

• Class: Long-acting amylin analogue

• Form: Lyophilized powder

• Molecular Formula: C₂₆₇H₄₄₁N₇₅O₈₅S₂

• Molecular Weight: ~6,036 Da

• Purity: ≥ 98% (HPLC verified)

• Dosage Strength: 5 mg per vial

• Appearance: White to off-white lyophilized powder

• Storage: Store in a cool, dry environment; refrigerate (35.6–46.4°F) after reconstitution; avoid repeated freeze–thaw cycles.

• Solubility: Dissolves in sterile water or bacteriostatic saline; gentle mixing recommended.

• Packaging: Sterile, sealed research-grade vial.

• Verification: Third-party tested for purity and peptide identity.